MaxCyte

MaxCyte Acquisitions (Net)

The Acquisitions (Net) of MaxCyte (MXCT) as of Sep 27, 2026 is 8.58 M USD. In the previous year, Acquisitions (Net) was 58.68 M USD — a change of -85.37% (lower).

Acquisitions (Net)

8.58 MUSD

YoY

-85.37%

Last updated:

Acquisitions (Net) of MaxCyte is 2026 8.58 M USD. Acquisitions (Net) of MaxCyte was 2025 58.68 M USD. It decreases by -85.37% lower compared to the previous year.

The MaxCyte Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2014
0.00 USD
Jan 1, 2018
-3.12 M USD
Jan 1, 2019
1.73 M USD
Jan 1, 2020
-14.51 M USD
Jan 1, 2021
-191.18 M USD
Jan 1, 2022
-6.35 M USD
Jan 1, 2023
58.68 M USD
Jan 1, 2024
8.58 M USD
The MaxCyte Acquisitions (Net) history
YEARAcquisitions (Net)YoY
8.58 MUSD-85.37%
58.68 MUSD-1,024.16%
-6.35 MUSD-96.68%
-191.18 MUSD+1,217.57%
-14.51 MUSD-938.73%
1.73 MUSD-155.45%
-3.12 MUSD—
0.00USD—
Access this data via the Eulerpool API

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Acquisitions (Net) of MaxCyte is 8.58 M USD in 2026.

Acquisitions (Net) of MaxCyte changed from 58.68 M USD to 8.58 M USD, representing a -85.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) MaxCyte since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s MaxCyte historically and in real time.

Access this data via the Eulerpool API

Cash Flow — MaxCyte

All Key Metrics — MaxCyte